IL-17A Blockade Treatment Success in Erythrodermic Pityriasis Rubra Pilaris

Main Article Content

Wylie Masterson
The University of Texas Health Science Center

Daniel Morse
The University of Texas MD Anderson Cancer Center

Omar Pacha
The University of Texas MD Anderson Cancer Center

Keywords

pityriasis rubra pilaris, secukinumab, IL-17, treatment, prp

Abstract

Background:


Pityriasis rubra pilaris is an inflammatory skin disease with no known etiology or treatment algorithm. PRP patients have an increase in cytokines IL-17A, IL-17F, and IL-22. There are case reports and series that study treatment with agents that block these cytokines, but more research is needed. Our objective is to add to the literature on treatment of PRP with IL-17A blockers.


Case:


A 63-year-old man presented with erythrodermic pityriasis rubra pilaris that was diagnosed after biopsy and laboratory tests ruled out other conditions such as psoriasis and Sezary syndrome. He was successfully treated with IL-17 blockade.


Conclusion:


Our case demonstrates the successful use of IL-17A blockade for PRP, which suggests that it could be an effective future treatment.

References

REFERENCES:
1. Wain T, Secukinumab in pityriasis rubra pilaris: A case series demonstrating variable response and the need for minimal clinical datasets. JAAD Case Rep.2018

2. Brembilla, Nicolo Costantino, Luisa Senra, and Wolf-Henning Boehncke. “The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.” Frontiers in immunology 9 (2018): 1682–1682. Web.

3. SONNEX, T. S et al. “The Nails in Adult Type 1 Pityriasis Rubra Pilaris: a Comparison with Sézary Syndrome and Psoriasis.” Journal of the American Academy of Dermatology 15.5 (1986): 956–960. Print.

4. Brown F, Badri T. Pityriasis Rubra Pilaris. [Updated 2020 Jun 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-.

5. Feldmeyer, Laurence et al. “Interleukin 23–Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.” JAMA dermatology (Chicago, Ill.) 153.4 (2017): 304–308. Web.

6. Liu, Taoming et al. “The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside.” Frontiers in immunology 11 (2020): 594735–594735. Web.

7. Wasilewska A, Winiarska M, Olszewska M, Rudnicka L. Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases. Postepy Dermatol Alergol. 2016;33(4):247- 252. doi:10.5114/ada.2016.61599

8. Schuster D, Pfister-Wartha A, Bruckner-Tuderman L, Schempp CM. Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab. JAMA Dermatol. 2016;152(11):1278–1279. doi:10.1001/jamadermatol.2016.3885

9. Schuster, Daniel et al. “Successful Treatment of Refractory Pityriasis Rubra Pilaris With Secukinumab.” JAMA dermatology (Chicago, Ill.) 152.11 (2016): 1278–1279. Web.

10. Wu, Kevin K, and Harry Dao. “Off-Label Dermatologic Uses of IL-17 Inhibitors.” The Journal of dermatological treatment ahead-of-print.ahead-of-print 1–7. Web.

11. Fala L. Cosentyx (Secukinumab): First IL-17A Antagonist Receives FDA Approval for Moderate-to-Severe Plaque Psoriasis. Am Health Drug Benefits. 2016;9(Spec Feature):60-63.

Article Sidebar

PDF
Published
Sep 13, 2021
DOI https://doi.org/10.25251/skin.5.5.14

Article Details

How to Cite
Masterson, W. ., Morse, D., & Pacha, O. (2021). IL-17A Blockade Treatment Success in Erythrodermic Pityriasis Rubra Pilaris. SKIN The Journal of Cutaneous Medicine, 5(5), 542–545. https://doi.org/10.25251/skin.5.5.14
Issue
Vol. 5 No. 5 (2021)
Section
Brief Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.